GlassScriptPhysician profile
Michael S Greenfield
NPI 1295873685
$3,705.94
in general payments reported to CMS, 2019-2025
28 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,350 · 2020: $320 · 2021: $154 · 2022: $212 · 2023: $354 · 2024: $99.96 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $597 · Education: $74.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $596.64 |
| Education | $74.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $500.72 | 2019-2023 | Afrezza |
| Novo Nordisk INC | $435.96 | 2019-2023 | Ozempic, Rybelsus |
| Amgen INC. | $377.15 | 2019-2025 | Repatha, Evenity, Prolia |
| Radius Health, INC. | $266.13 | 2019-2023 | Tymlos |
| Sanofi-Aventis U.S. LLC | $247.73 | 2019-2023 | |
| Abbvie INC. | $229.18 | 2019-2024 | |
| Lilly USA, LLC | $210.97 | 2019-2023 | Jardiance |
| Insulet Corporation | $175.61 | 2019-2021 | |
| Abbott Laboratories | $163.87 | 2022-2025 | Freestyle Libre 3 |
| Endo Pharmaceuticals INC. | $136.65 | 2020-2021 | |
| Corcept Therapeutics | $128.36 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.75 | 2019-2023 | Jardiance |
| Shire North American Group INC | $98.65 | 2019 | |
| Becton, Dickinson and Company | $92.73 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $84.56 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $66.00 | 2023-2025 | Nexletol, Contrave |
| Alexion Pharmaceuticals, INC. | $64.53 | 2019 | |
| Madrigal Pharmaceuticals | $46.80 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $44.62 | 2019-2022 | |
| Lifescan, INC. | $44.10 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $36.39 | 2019 | |
| Dexcom, INC. | $32.78 | 2023 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $24.04 | 2025 | |
| Vivus LLC | $23.26 | 2019 | |
| Agios Pharmaceuticals, INC. | $19.98 | 2025 | Pyrukynd |
| Medtronic Minimed, INC. | $17.06 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.36 | 2024 | Gvoke Hypopen |
| Senseonics, Incorporated | $5.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Greenfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.